Drug development for metastatic castration-resistant prostate cancer: Current status and future perspectives

Future Oncology

Volumn 7, Issue 4, 2011, Pages 551-558

  Lassi, Kiran ^a   Dawson, Nancy A ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

androgen receptor; cabazitaxel; castration resistant; circulating tumor cell; immunotherapy; novel therapy; prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AFLIBERCEPT; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTISENSE OLIGONUCLEOTIDE; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CANCER VACCINE; CUSTIRSEN; CYTOTOXIC AGENT; DENOSUMAB; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; EPOTHILONE B; EPOTHILONE DERIVATIVE; IPILIMUMAB; IXABEPILONE; MITOXANTRONE; PICOPLATIN; PREDNISONE; PROSTVAC; PROTEIN TYROSINE KINASE INHIBITOR; PROVENGE; RD 162; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ASTHENIA; BACKACHE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASTRATION; CHILL; COLITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEVER; HUMAN; HYPERTENSION; JAW OSTEONECROSIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CASTRATION; DRUG DISCOVERY; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 79953711155     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.14     Document Type: Review

References (38)

1. Ryan CJ, Smith MR, Fong L et al.: Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28(9), 1481-1488 (2010).
2. Reid AHM, Attard G, Danila DC et al.: Signifcant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28(9), 1489-1495 (2010).
3. Danila DC, Morris MJ, de Bono JS et al.: Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28(9), 1496-1501 (2010).
4. Scher HI, Beer TM, Higano CS et al.: Antitumor activity of MDV3100 in a Phase I/II study of castration-resistant prostate cancer. J. Clin. Oncol. 27 (15 Suppl.) Abstract 5011 (2009).
5. de Bono JS, Oudard S, Ozguroglu M et al.: Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castrate resistant prostate cancer previously treated with docetaxel: fnal results of the multinational Phase III trial (TROPIC). Lancet 376(9747), 1119-1120 (2010).
6. Sharp SY, O'Neill CF, Rogers P et al.: Retention of activity by the new generation platinum agent AMD0473 in four human tumor cell lines possessing acquired resistance to oxaliplatin. Eur. J. Cancer 38, 2309-2315 (2002). (Pubitemid 35346473)
7. De Jager RL, Roman DL, Lopatkin NA et al.: Phase II study of picoplatin with docetaxel and prednisone in frst-line treatment of castration resistant prostate cancer (CRPC). Presented at: 2010 Genitourinary Cancer Symposium. San Francisco, CA, USA, 5-7 March 2010.
8. Rosenberg JE, Weinberg VK, Kelly WK, et al.: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized Phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110, 556-563 (2007). (Pubitemid 47106144)
9. Hussain M, Tangen CM, Lara PN Jr et al.: Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J. Clin. Oncol. 23(34), 8724-8726 (2005).
10. Harztark AL, Rosenberg JE, Weinberg VK et al.: Ixabepilone, mitoxantrone and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a Phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer, DOI: 10.1002/cncr.25810 (2010) (Epub ahead of print).
11. Beardsley ES, Venner F, Eigl B et al.: A Phase II study of Patupilone in patients (pts) in metastatic castrate resistant prostate cancer (CRPC) who have progressed after docetaxel. J. Clin. Oncol. 27(15 Suppl.), Abstract 5139 (2009).
12. De Souza PL, Mellado B, Pfster C, et al.: Randomized Phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naive, metastatic, castrate-resistant prostate cancer (CRPC). J. Clin. Oncol. 28(7 Suppl.), Abstract 4553 (2010).
13. Nelson JB, Hedican SP, George D et al.: Identifcation of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944-949 (1995).
14. Carducci, MA, Saad F, Abrahamsson PA et al.: A Phase 3 randomized controlled trial of the effcacy and safety of astrasentan in men with metastatic hormone refractory prostate cancer. Cancer 110(9), 1959-1966 (2007). (Pubitemid 350036854)
15. Tru mp DL, Payne H, Miller K et al.: Safety and effcacy of the specifc endothelin A receptor antagonist zibotentan plus docetaxel in patients with hormone refractory prostate cancer: results of a Phase I study Presented at: 2010 Genitourinary Cancer Symposium. San Francisco, CA, USA, 5-7 March 2010.
16. James N, Caty A, Borre M et al.: Safety and effcacy of the specifc endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate ca ncer and bone metastases who were pain-free or mildly symptomatic: a double-blind, placebo-controlled, randomized, Phase 2 trial. Eur. Urol. 55(5), 1112-1123 (2008).
17. Higano CS, Schellhammer PF, Small EJ et al.: Integrated data from 2 randomized double-blind placebo controlled Phase 3 trials of active cellular-immunotherapy with sipleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009).
18. Kantoff P, Higano CS, Berger ER et al.: Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration resistant prostate cancer (CRPC). Presented at: 2010 Genitourinary Cancer Symposium. San Francisco, CA, USA, 5-7 March 2010.
19. Kantoff PW, Schuetz TJ, Blumenstein BA et al.: Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate can cer. J. Clin. Oncol. 28, 1099-1105 (2010).
20. Tollefson MK, Karnes RJ, Thompson RH et al.: A randomized Phase II study of ipilimumab with androgen ablation verus androgen ablation alone in patients with advanced prostate cancer. Presented at: 2010 Genitourinary Cancer Symposium. San Francisco, CA, USA, 5-7 March 2010.
21. Slovin F, Beer TM, Higano CS et al.: Initial Phase II experience of ipilimumab (IPI) alone and in c ombination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 27(15 Suppl.), Abstract 5138 (2009).
22. Di Lorenzo G, Figg W, Fossa S et al.: Combinati on of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase II study. Eur. Urol. 54(5), 1089-1096 (2008).
23. Ning Y-M, Gulley JL, Arlen PM et al.: Trial of bevacizum ab, thalidomide, docetaxel and prednisone in patients with metastatic castration resistant prostate cancer. J. Clin. Oncol. 28(12), 2070-2076 (2010).
24. Kelly WK, Halabi S, Carducci MA et al.: A randomiz ed, double-blind, placebo controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrate-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J. Clin. Onco l. 28(7 Suppl.), Abstract LBA4511 (2010).
25. Dahut WL, Scripture C, Posadas E et al.: A Phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 14(1), 209-214 (2008). (Pubitemid 351377997)
26. Sonpavde G, Periman PO, Bernold D et al.: Sutinib malate for metastatic castration-resistant prostate cancer after docetaxel based chemotherapy. Ann. Oncol. 21(2), 319-324 (2010).
27. Castellano E, Gonzalez-Larriba J, Anton-Aparicio LM, Cassinello J, Grande Pulido E, Esteban E: Clinical, serological, radiographic beneft with sunitinib as a single agent in metastatic castrate resistant prostate cancer (HRPC) patients. Presented at: 2010 Genitourinary Cancer Symposium. San Francisco, CA, USA, 5-7 March 2010.
28. Safarenijad MR: Safety and Effcacy of Sorafenib with castrate resistant prostate cancer. Urol. Oncol. 28(1), 21-27 (2010).
29. Aragon-Ching, Jain L, Gulley JL et al.: Final analysis of a Phase II trial using sorafenib in castrate resistant prostate cancer. BJU Int. 103(12), 1636-1640 (2009).
30. Adelberg D, Karakunnel JJ, Gulley JL et al.: A Phase II study of cediranib in post-docetaxel castration resistant prostate cancer (CRPC). Presented at: 2010 Genitourinary Cancer Symposium. San Francisco, CA, USA, 5-7 March 2010.
31. Bratt O, Haggman M, Ahlgren G et al.: Open-label, clinical Phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br. J. Cancer 101, 1233-1240 (2009).
32. Pili R, Haggman M, Stadler WM et al.: A randomized, multicenter, international Phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC). J. Clin. Oncol. 28(7 Suppl.), Abstract 4510 (2010).
33. Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B: Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev. 21(1), 79-92 (2002). (Pubitemid 35210177)
34. Chi KN, Hotte SJ, Yu EY et al.: A randomized Phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer. J. Clin. Oncol. 28(27), 4247-4254 (2010).
35. Saad F, Hotte SJ and North SA et al.: A Phase II randomized study of clustirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J. Clin. Oncol. 26, Abstract 5002K (2008).
36. Fizazi MA, Carducci MR, Smith R et al.: A randomized Phase III trial of denosumab versus zolend ronic acid in patients with bone metastases from castration resistant prostate cancer. J. Clin. Oncol. 28(7 Suppl.), Abstract LBA4507 (2010).
37. Stopeck AT, Lipton A, Body J-J et al.: Denosumab compared with zolend ronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double blind study J. Clin. Oncol. 28, 5132-5139 (2010).
38. Henry DH, von Moos R, Hungria V et al.: Delaying skeletal related events in a randomized Phase III study of denosumab versus zolendronic acid in patients with advanced cancer. J. Clin. Oncol. 28(15 Suppl.), Abstract 9133 (2010).